Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
Related Articles
Intentional Treatment Sequencing Strategies Optimize SCLC and NSCLC Management
Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.
FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.
Dr Mehnert on the Efficacy of Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab in Unresectable Melanoma
Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.
Molecular Profiling in Pancreatic Cancer: RAS Testing and Codon-Specific Interpretation
Panelists highlighted how recent breakthroughs in KRAS-specific inhibitors—such as those targeting G12C, G12D, and G12V mutations—are transforming the management of pancreatic cancer, underscoring the importance…
Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress
Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.
LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC
Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Retifanlimab Presents a New Treatment Option for Locally Recurrent or Metastatic SCAC
Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.